Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12848842 | 0.84 | — | — | |
| SCHEMBL12848449 | 0.83 | RORC (0.36) | KDM4EALDH1A1 | |
| SCHEMBL12848849 | 0.81 | HTR1F (0.40) | NPSR1ALDH1A1 | |
| SCHEMBL12848839 | 0.80 | SLC27A1 (0.36) | ADORA3ADORA2AADORA2BADORA1NPSR1 | |
| SCHEMBL12848914 | 0.80 | HRH3 (0.33) | ADORA3ADORA2AADORA2BADORA1NPSR1 | |
| SCHEMBL12848737 | 0.70 | ALOX15 (0.31) | TSHR | |
| SCHEMBL12848841 | 0.65 | MAPT (0.37) | KDM4EALDH1A1 | |
| SCHEMBL4999489 | 0.65 | HDAC4 (0.35) | ADORA2AADORA1KDM4E | |
| SCHEMBL12848559 | 0.64 | TP53 (0.37) | KDM4E | |
| SCHEMBL12848445 | 0.63 | MEN1 (0.38) | KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110052643-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110052643-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | TSLP, NFATC1, IL5 | TSHR 4453/4885ADORA3 763/4885ADORA2A 445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.